Indefinite Delivery Contract SPE2DU25D9352

The Defense Logistics Agency (DLA) has awarded a single-award Indefinite Delivery Contract (IDC) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, to provide worldwide pharmaceutical support to various Department of Defense (DoD) customers. The $499,999,999 IDC, valid through November 2026, enables DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the medical supply needs of military health facilities globally.

The IDC is part of the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) acquisition, which aims to establish multiple regional prime vendor contracts to ensure a diverse and resilient pharmaceutical supply chain. The PPV-G GEN V solicitation, expected to be issued in March 2024, will cover a 30-month base period with three 30-month option periods, with an estimated total value of $30.3 billion. The contract will be awarded on a lowest price technically acceptable basis, with the potential use of reverse auctions to determine the final distribution fees.